GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Burning Rock Biotech Ltd (NAS:BNR) » Definitions » Price-to-Free-Cash-Flow

Burning Rock Biotech (Burning Rock Biotech) Price-to-Free-Cash-Flow : N/A (As of May. 31, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Burning Rock Biotech Price-to-Free-Cash-Flow?

As of today (2024-05-31), Burning Rock Biotech's share price is $7.15. Burning Rock Biotech's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.48. Hence, Burning Rock Biotech's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Burning Rock Biotech's Price-to-Free-Cash-Flow or its related term are showing as below:

During the past 7 years, Burning Rock Biotech's highest Price-to-Free-Cash-Flow Ratio was 2290.00. The lowest was 213.89. And the median was 394.35.

BNR's Price-to-Free-Cash-Flow is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 26.06
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Burning Rock Biotech's Free Cash Flow per Share for the three months ended in Mar. 2024 was $-0.54. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-2.48.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -2.10% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 8.50% per year.

During the past 7 years, Burning Rock Biotech's highest 3-Year average Free Cash Flow per Share Growth Rate was 2.60% per year. The lowest was -17.40% per year. And the median was -3.85% per year.


Burning Rock Biotech Price-to-Free-Cash-Flow Historical Data

The historical data trend for Burning Rock Biotech's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Burning Rock Biotech Price-to-Free-Cash-Flow Chart

Burning Rock Biotech Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial - - - - -

Burning Rock Biotech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Burning Rock Biotech's Price-to-Free-Cash-Flow

For the Diagnostics & Research subindustry, Burning Rock Biotech's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Burning Rock Biotech's Price-to-Free-Cash-Flow Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Burning Rock Biotech's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Burning Rock Biotech's Price-to-Free-Cash-Flow falls into.



Burning Rock Biotech Price-to-Free-Cash-Flow Calculation

Burning Rock Biotech's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=7.15/-2.477
=N/A

Burning Rock Biotech's Share Price of today is $7.15.
Burning Rock Biotech's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.48.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Burning Rock Biotech  (NAS:BNR) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Burning Rock Biotech Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Burning Rock Biotech's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Burning Rock Biotech (Burning Rock Biotech) Business Description

Traded in Other Exchanges
Address
No. 5, Xingdao Ring Road North, International Bio Island, Guangzhou, CHN, 510005
Burning Rock Biotech Ltd is a cancer diagnostics company. Its products include OncoScreen Plus and ColonCore. The company has developed various cancer detection products, involving tumor targeting, differentiation of benign and malignant tumors, monitoring of small residual lesions, prediction of tumor recurrence progress, and detection of tumor sensitivity. It offers 12 NGS-based cancer therapy selection tests comprising a broad range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer, using both tissue and liquid biopsy samples.